Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 ““ PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): … Continue reading Mary O’Brien, MD @drMaryOBr @royalmarsdenNHS #ASCO22 #OncoTwitter Phase III PEARLS/KEYNOTE-091 Discussion